MARKET

ZIVO

ZIVO

Zivo Bioscience Inc
NASDAQ
3.345
+0.025
+0.76%
Closed 16:00 02/08 EST
OPEN
3.421
PREV CLOSE
3.320
HIGH
3.421
LOW
3.275
VOLUME
1.90K
TURNOVER
--
52 WEEK HIGH
4.600
52 WEEK LOW
2.160
MARKET CAP
31.51M
P/E (TTM)
-3.2223
1D
5D
1M
3M
1Y
5Y
9 Consumer Staples Stocks Moving In Tuesday's Intraday Session
Benzinga · 12/13/2022 17:33
BRIEF-Zivo Bioscience Has Received Notice Of Delisting From Nasdaq
Reuters · 11/29/2022 21:43
BRIEF-Zivo Bioscience Establishes Zivolife Agtech Business
Reuters · 10/24/2022 22:26
ZIVO Bioscience Announces Plans For A New Streamlined, Focused Corporate Structure And Establishes The ZIVOLife Agtech Business
Benzinga · 10/24/2022 20:19
ZIVO Bioscience CEO Issues Letter to Shareholders
BLOOMFIELD HILLS, Mich., September 23, 2022--Zivo Bioscience, Inc. (NASDAQ: ZIVO), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, today issued th...
Business Wire · 09/23/2022 12:00
BRIEF-Zivo Bioscience Inc Announces Receipt Of A Letter From The U.S. Department Of Agriculture's Center For Veterinary Biologics
BRIEF-Zivo Bioscience Inc Announces Receipt Of A Letter From The U.S. Department Of Agriculture's Center For Veterinary Biologics
Reuters · 08/23/2022 11:43
Zivo Bioscience Said USDA Letter Affirmed Agency Has Claimed Jurisdiction for Reviewing the Company's Novel Immune-Modulating Biologic for Treating Coccidiosis in Broiler Chickens
In August 2022, Zivo Bioscience, Inc. (the "Company") announced receipt of a letter from the U.S. Department of Agriculture's (USDA) Center for Veterinary Biologics (CVB) affirming that the agency has claimed jurisdiction for reviewing the Company's novel immune-modulating biologic for treating coccidiosis in broiler chickens.
Benzinga · 08/23/2022 11:38
Why Amazon Shares Traded Lower; Here Are 74 Biggest Movers From Yesterday
Gainers Bright Minds Biosciences Inc. (NASDAQ: DRUG) shares jumped 72.8% to close at $2.16 on Monday as the stock continued to see momentum despite the company last week announcing it is not aware of any developments that would explain the recent surge.
Benzinga · 08/23/2022 10:11
More
About ZIVO
Zivo Bioscience, Inc. is a research and development company. The Company is engaged in developing bioactive compounds derived from its algal culture, targeting human and animal diseases, such as poultry coccidiosis, bovine mastitis, human cholesterol, and canine osteoarthritis. Its algal biomass contains vitamin A, protein, iron, fatty acids, non-starch polysaccharides and other micronutrients. Its products include Poultry Gut Health, Bovine Mastitis, Canine Joint Health, Human Immune Modulation, Algal biomass for human consumption, Algal biomass for animal feed and Biomass for supporting skin health / anti-aging. The Company is also engaged in licensing and selling natural bioactive ingredients derived from their algae cultures to animal, human and dietary supplement and medical food manufacturers.

Webull offers kinds of Zivo Bioscience Inc stock information, including NASDAQ:ZIVO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ZIVO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ZIVO stock methods without spending real money on the virtual paper trading platform.